Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast CancerMaria Lucibello1* and Filippo De Braud2
- *Corresponding Author:
- Maria Lucibello
Institute of Translational Pharmacology
National Research Council, Rome, Italy
Tel: +39 06 45488002
E-mail: [email protected]
Received date: December 29, 2015 Accepted date: March 01, 2016 Published date: March 07, 2016
Citation: Lucibello M, De Braud F (2016) Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. Chemo Open Access 5:196. doi:10.4172/2167-7700.1000196
Copyright: © 2016 Lucibello M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The development of resistance to chemotherapeutics is still a severe event in cancer patients. One of the major obstacles to the effectiveness of cancer therapies is the development of side effects and resistance to therapy. The characterization of novel biomarkers that support a more aggressive phenotype may provide new diagnostic tools and new opportunities for cancer therapy. In the context of breast cancer disease, the phosphorylated form of Translationally controlled tumor protein (phospho-TCTP) appears a new prognostic factor for aggressive breast cancer and tumor progression. Dihydroartemisinin (DHA) is a novel approach to molecular targeted therapies, or combination regimens in advance breast cancer.